Crossmark

Changes in Basal and Bolus Insulin Requirements with Tirzepatide as an Adjunctive Therapy in Adults with Type 1 Diabetes Using Tandem Control-IQ

Published Online: 2024-05-14

Published Print: 2024-07

Authors

Karakus, Kagan E.

Klein, Matthew P.

Akturk, Halis K.

Shah, Viral N. https://orcid.org/0000-0002-3827-7107
License Information

Text and Data Mining valid from 2024-05-14

Version of Record valid from 2024-05-14
More Information

Article History

Received: 2 April 2024

Accepted: 15 April 2024

First Online: 14 May 2024

Declarations

:

: The author declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Halis K. Akturk received research support through University of Colorado from Dexcom, Tandem Diabetes, Senseonics, Medtronic, Eli Lilly, REMD Biotherapeutics, IM Therapeutics, and IAFMS and received honoraria through University of Colorado from Senseonics and Mannkind for advisory board attendance. Viral N. Shah received research support from Novo Nordisk, Insulet, and Tandem Diabetes Care and received honoraria from Dexcom, Embecta, Insulet, Ascensia Diabetes Care, Tandem Diabetes Care, Genomelink and LumosFit for consulting or speaking arrangements. Kagan E. Karakus and Matthew P. Klien do not report any conflicts of interest.

: This study was approved by the Colorado Multiple Institutional Review Board under the exempt category due to the retrospective nature of the study.

Document is current